References:

Vahdatpour C, Collins D, Goldberg S. Cardiogenic Shock. J Am Heart Assoc. 2019;8(8):e011991.

Shaefi S, O'Gara B, Kociol RD, et al. Effect of cardiogenic shock hospital volume on mortality in patients with cardiogenic shock. J Am Heart Assoc. 2015;4(1):e001462.

Subramaniam AV, Barsness GW, Vallabhajosyula S, Vallabhajosyula S. Complications of Temporary Percutaneous Mechanical Circulatory Support for Cardiogenic Shock: An Appraisal of Contemporary Literature. Cardiol Ther. 2019;8(2):211-228.

* PercAssist internal market estimates based on incidence/growth data for cardiogenic shock and heart failure.

PercAssist eVAD™ and PercAssist eVAD™ System are trademarks of PercAssist, Inc.

The PercAssist eVAD™ System technology is under development and is for investigational use only. Not yet approved by FDA and not available for commercial distribution in the United States or any other market.